Symposien Donnerstag

Änderungen im Programmablauf vorbehalten.

Saal 1 14:30 - 16:00 01.10.2015
Symposium Do17
Corneal surgery and eye banking: Can eye banks fulfill the need for versatile ocular tissue? – Joint Symposium of the Sektion DOG-Tissue Transplantation and Biotechnology and the European Eye Bank Association (EEBA)
Vorsitzende/r: Philip Maier (Freiburg), John Armitage (Bristol)

Different aspects regarding the need of a corneal surgeon and the possibilities and problems to fulfill these by an eye bank shall be discussed. The following topics will be focused on: HLA typing in the age of lamellar keratoplasty, usefulness of keratoplasty registers, legal aspects regarding importing and exporting ocular tissue in Europe, supply with therapeutic grafts, precut tissue for DMEK and setting up limbal stem cell facility. The European Eye Bank Association (EEBA) is a technical-scientific organization comprising individual members from 92 eye banks from 23 European countries. Founded with the simple objective of sharing information regarding eye banking, the Association is today the leading pan-national association in Europe dedicated to the advancement of eye banking and an authoritative reference point for eye banks wishing to work according to quality standards.
Referent/in: John Armitage (Bristol)
For penetrating keratoplasty (PK), allograft rejection accounts for 30-40% of graft failures. European studies generally support a benefit of HLA class I matching. Lamellar grafts (DALK, DSAEK, DMEK) can still suffer rejection but the risk is rather lower than for PK. The role of HLA matching in lamellar keratoplasty will be explored.
Referent/in: Margareta Claesson Armitage (Mölndal)
A registry improves our understanding of the factors that influence graft outcome. It provides "real world" outcomes vs single centre. Combining patient reported outcome with clinical outcome helps define the true benefit to patients.
Referent/in: Richard McGeehan (Bruxelles)
On April 8, 2015 the European Commission adopted a new Directive laying down procedures for verifying the quality and safety of tissues and cells imported into the European Union. This Directive will place new requirements on a number of actors, including those involved in the import of tissues and cells from third countries.
Referent/in: Jan Schroeter (Berlin)
Severe infectious and non-infectious inflammatory corneal diseases might require an urgent keratoplasty as ultimate treatment option. The graft survival rate in those patients is reduced and mainly depended on the underlying corneal pathology and the delay of surgery. Therefore donor corneas with reduced central endothelial cell count are appropriate in many cases. This allows the cornea bank an immediate allocation of a corneal graft when needed.
Referent/in: Philip Maier (Freiburg)
Although functional results following DMEK are better than after penetrating keratoplasty or DSAEK, DSAEK seems still to be the standard procedure as surgeons fear to lose grafts during the preparation process. Therefore, more and more eye banks offer DMEK grafts as precut tissue that can directly be used by the surgeon. Here, we analysed the functional results and complications rates for a new precut technique compared to direct preparation performed just before surgery.
Referent/in: Stefano Ferrari (Venedig)
According to Regulation (EC) 1394/2007 on Advanced Therapy Medicinal Products (ATMPs), manipulation of limbal stem cells for clinical applications has to be carried out in GMP cell factories. For hospitals and tissue banks wanting to provide ATMPs many challenges lie ahead, including costs for setting up and maintaining such facilities. In addition, the recent marketing authorization for a cultured limbal stem cell-based treatment by EMA leads to a further dilemma: hospital exemption versus marketing authorization?